• Hero Banner
  • ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Products
Recalls
Regulatory
Digital Media
dvm360 LIVE!™
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspectives™
Weekly Newscast
dvm360 Insights™
Publications
All Publications
dvm360
Firstline
Supplements
Top Recommended Veterinary Products
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Pharmacy
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Buying or Selling a Practice
Hospital Design
Leadership & Personal Growth
Personnel Management
Practice Finances
Practice Operations
Technology
Wellbeing & Lifestyle
Continuing Education
Conferences
Live Conferences
Conference News
Conference Proceedings
Resources
CBD in Pets
Contests
Veterinary Heroes
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Top Recommended Veterinary Products
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2023 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Advertisement
By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2023 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

Phibro Animal Health Corporation and Rejuvenate Bio to develop canine mitral valve disease gene therapy

June 27, 2022
dvm360 Staff

They strive to create a novel gene therapy that stops MVD before it causes heart failure and reverses some or all heart damage

Phibro Animal Health Corporation and Rejuvenate Bio, Inc. have partnered for the development and commercialization of canine mitral valve disease (MVD) gene therapy.

"We have confidence that our collaboration with Rejuvenate Bio will meet our goal to bring about an effective gene therapy that will revolutionize the way veterinarians treat MVD, adding healthy, happy years to the life of a dog who suffers from this disease,” stated Thomas Zerzan, president of the companion animal division at Phibro Animal Health, in a company release.1

MVD is the most common congenital heart disease in dogs, accounting for over 70% of all canine heart disease and it is a leading cause of death for cavalier King Charles spaniels.2,3 The American Cavalier King Charles Spaniel Club gifted support to Rejuvenate Bio for this research.

According to the release, existing therapies have been proven to slow the course of MVD, but there is no therapy that stops the disease or reverses the damage. Thus, Phibro and Rejuvenate Bio's breakthrough gene therapy aims to address the latter.

Advertisement

“We are excited to work with Phibro to make the treatment of MVD a reality. We expect to file for a conditional approval as early as 2023. We view this as a first step to tackling numerous age-related diseases that affect the animals we love,” Daniel Oliver, CEO of Rejuvenate Bio, expressed.

Based on research and findings, the gene therapy for MVD was revealed in the laboratory at Harvard Medical School and the Wyss Institute by genetics scientist and startup founder, George Church.1

References

  1. Phibro Animal Health Corporation and Rejuvenate Bio announce agreement to develop gene therapy for mitral valve disease in canines. News release. Phibro Animal Health Corporation. June 22, 2022. Accessed June 27, 2022. https://www.businesswire.com/news/home/20220622005079/en
  2. Parker, HG, Kilroy-Glynn, P. Myxomatous mitral valve disease in dogs: does size matter? J Vet Cardiol. 2012;14(1):19–29. https://doi.org/10.1016/j.jvc.2012.01.006
  3. Mitral valve disease and the cavalier King Charles spaniel. Cavalier health. Accessed June 27, 2022. https://cavalierhealth.org/mitral_valve_disease.htm

Related Content:

CardiologyRolesAssociates
Can our Pride panel answer these LGBTQ+ trivia questions?
Can our Pride panel answer these LGBTQ+ trivia questions?
Creating inclusive spaces for the LGBTQ+ community in vet med
Creating inclusive spaces for the LGBTQ+ community in vet med
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more
Happy Pride Month, Hill's launches Prescription Diet ONC Care, and more

Advertisement

Latest News

Humanimal Trust joins World Federation for Animals

News wrap-up: This week’s headlines, plus Kansas State University College of Veterinary Medicine presents Temple Grandin, PhD, MS, with an honorary degree

Can our Pride panel answer these LGBTQ+ trivia questions?

Creating inclusive spaces for the LGBTQ+ community in vet med

View More Latest News
Advertisement